Genentech’s Ocrevus data show NfL may be a biomarker for predicting future disability outcomes
– Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in
Read more
Roche
Synlogic in clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine for advanced solid tumors
Synlogic in clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine for advanced solid tumors
Read more
Roche Presents Data from Biognosys for Use of Discovery Proteomics in Clinical Trials
Roche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical
Read more
Tecentriq combination fast approval for PD-L1-positive, metastatic triple-negative breast cancer
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Read more
Roche buys Spark Therapeutics for $4.3 billion
Roche will fully buy Spark Therapeutics at a price of $114.50 per share in an all-cash transaction, or for $4.3
Read more
Roche to get quicker review of its anti cancer Rituxan combination, in August
Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Read more
Roche working to bring this Tecentriq-based combination to people with non-squamous non-small cell lung cancer
Roche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ALK genomic tumour aberrations.
Read more
BioPorto nets deal with Roche for distribution of test on Roche’s cobas analysers
BioPorto and Roche agreed that BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche’s cobas c
Read moreBoehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked
Read more
Horizon Discovery enters into agreement with Roche Diagnostics
Horizon Discovery Group has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.
Read more